이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Mayne Pharma Group 관리

관리 기준 확인 1/4

Mayne Pharma Group's CEO는 Shawn O’Brien, Oct2022 에 임명되었습니다 의 임기는 1.67 년입니다. 총 연간 보상은 A$ 1.50M, 44.2% 로 구성됩니다. 44.2% 급여 및 55.8% 보너스(회사 주식 및 옵션 포함). 는 € 105.80K 가치에 해당하는 회사 주식의 0.046% 직접 소유합니다. 105.80K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 2.3 년입니다.

주요 정보

Shawn O’Brien

최고 경영자

AU$1.5m

총 보상

CEO 급여 비율	44.2%
CEO 임기	1.7yrs
CEO 소유권	0.05%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	2.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Shawn O’Brien 의 보수는 Mayne Pharma Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	n/a	n/a	-AU$274m
Sep 30 2023	n/a	n/a	-AU$296m
Jun 30 2023	AU$2m	AU$663k	-AU$317m

보상 대 시장: Shawn 의 총 보상 ($USD 1.00M )은 German 시장( $USD 758.96K ).

보상과 수익: Shawn 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Shawn O’Brien (65 yo)

1.7yrs

테뉴어

AU$1,502,156

보상

Mr. Shawn Patrick O'Brien, B.Sc has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'Brien is a found...

리더십 팀

이름	위치	테뉴어	보상	소유권
Shawn O’Brien	CEO, MD & Director	1.7yrs	AU$1.50m	0.046% A$ 108.6k
Aaron Gray	Chief Financial Officer	1.8yrs	AU$1.30m	0.016% A$ 39.0k
Kimberly Parker	Executive VP & General Counsel	2.4yrs	데이터 없음	데이터 없음
Brant Schofield	Executive Vice President of Corporate Development	3.4yrs	AU$1.29m	데이터 없음
Erinn Nathaniel	Director of Global Human Resources	1.4yrs	데이터 없음	데이터 없음
Daniel Moore	Executive Vice President of Commercial	4.8yrs	데이터 없음	데이터 없음
Frank Casty	Executive VP & Global Chief Medical Officer	1.4yrs	데이터 없음	데이터 없음
Brenton Walter	Financial Controller	19.9yrs	데이터 없음	데이터 없음
Laura Loftus	Associate General Counsel & Company Secretary	4.3yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

경험이 풍부한 관리: HG6 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Shawn O’Brien	CEO, MD & Director	1.7yrs	AU$1.50m	0.046% A$ 108.6k
Frank Condella	Independent Non-Executive Chairman	6.1yrs	AU$297.04k	0.081% A$ 193.4k
Bruce Robinson	Independent Non-Executive Director	9.8yrs	AU$166.43k	0.039% A$ 93.1k
Patrick Blake	Independent Non-Executive Director	6yrs	AU$212.39k	0.027% A$ 64.8k
Ann Custin	Independent Non-Executive Director	2.3yrs	AU$212.39k	0.026% A$ 62.6k
Kathryn MacFarlane	Independent Non-Executive Director	2.3yrs	AU$212.42k	0.047% A$ 111.4k
Anne Lockwood	Director	less than a year	데이터 없음	데이터 없음
David Petrie	Independent Non-Executive Director	1.8yrs	AU$137.96k	데이터 없음

2.3yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: HG6 의 이사회는 경험(평균 재직 기간 2.3 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Mayne Pharma Group 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

High number of new directors

Recent updates

No longer forecast to breakeven

New minor risk - Profitability

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

New minor risk - Share price stability

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Now 48% undervalued after recent price drop

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021)

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Mayne Pharma Expands U.S Dermatology Portfolio

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Forecast to breakeven in 2023

Independent Non-Executive Director recently bought €85k worth of stock

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020)

Revenue beats expectations

Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021

Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States

New 90-day high: €0.24

Mayne Pharma Group Limited Provides Update on Women's Health Pipeline

Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer

Full year earnings released

Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020

Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령